Eton Corp (ETON) Enterprise Value to EBITDA Ratio

Public company logo of etonpharma.com (ETON)

The price visualization for Eton Pharmaceuticals (ETON) on GURU.Markets shows an EV/EBITDA ratio of 39.39. The company's business relies on the commercialization of undervalued endocrine drugs for pediatricians. High parental loyalty to specific pediatric drug formulations ensures a steady patient inflow supported by the FDA. The team of rare drug experts is motivated by direct financial participation in the success of new developments.

Eton Pharmaceuticals Inc - ETON Company Value to EBITDA (period 11/23/2025 - 11/15/2026)

Comprehensive metric breakdowns and analytics for Eton Pharmaceuticals Inc (ETON)

- current price and projected stock value:
Stock Price etonpharma.com|ETON - Analyst Median Target
- market capitalization details:
Market Valuation Eton Pharmaceuticals|ETON - Full Business Value
- business book valuation details:
Book Value per Share Eton Pharmaceuticals|ETON - Total Stockholders' Equity|Market Capitalization to Book Value Ratio etonpharma.com|ETON - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Eton Pharmaceuticals|ETON - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Eton Pharmaceuticals, Inc.|ETON - Company Aggregate Indebtedness|Debts to Book Capitalization Eton Pharmaceuticals Inc|ETON - Company Long-Term Loans and Borrowings|Company Short-Term Debts Eton Pharmaceuticals|Quick Liquidity etonpharma.com
- financial results and valuation multiples details:
ETON - Final Profit|Expected Profit Eton Pharmaceuticals|ETON - Price to Earnings Ratio|Forward P/E Multiple etonpharma.com|ETON - PEG Multiple|EV/EBITDA Multiple Eton Corp|ETON - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Eton Pharmaceuticals|ETON - Earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months etonpharma.com|ETON - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Eton Pharmaceuticals
- revenue and sales details:
ETON - Company Sales Volume|Company Future Sales Volume Eton Pharmaceuticals|ETON - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio Eton Pharmaceuticals|ETON - Trailing Twelve Months Sales Growth
Fundamental valuation:Eton Pharmaceuticals ETON
Manufactured products of Eton Pharmaceuticals, Inc.

The EV/EBITDA multiple determines the total enterprise value of a business relative to its operating profit before depreciation and interest. By analyzing the dynamic EV/EBITDA value of a company, an investor assesses the real value of assets while accounting for the debt load. Low indicators may signal undervaluation, yet they require caution due to "value trap" risks. For Eton Pharmaceuticals (ETON), this metric is critical during expansion into niche pediatric drugs with low competition.

Key competitors

EV/EBITDA Multiple VRTX (vrtx.com)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BridgeBio Pharma Inc (BBIO)|Enterprise Value to EBITDA Ratio BGM|Enterprise Value to Operating Income Before Depreciation COGT (Cogent Biosciences, Inc.)|Enterprise Value to EBITDA Ratio XERS (Xeris Biopharma Holdings)|KROS (Keros Therapeutics Inc) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arcturus Therapeutics Holdings Inc. ARCT|KMDA (Kamada Corp) - Company Value to Operating Income Before Depreciation Ratio|Fulcrum Therapeutics - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation ABEO (abeonatherapeutics.com)|MREO: EV/EBITDA Multiple|Protalix BioTherapeutics Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization pliantrx.com|APLT: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization aileronrx.com (RNTX)|Enterprise Value to EBITDA Ratio Gelteq GELS|EV/EBITDA Multiple AYTU (Aytu BioPharma Inc)|EV/EBITDA Multiple Chemomab CMMB|SRXH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio PLRZ|AEZS: EV/EBITDA Multiple|Company Value to EBITDA Cyclo Therapeutics (CYTH)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inozyme Pharma Inc.|Enterprise Value to Operating Income Before Depreciation RPHM (Reneo Pharmaceuticals, Inc.)|EV/EBITDA Multiple CSCI